Blanket Purchase Agreement V797P7323A-36C24221A0050

The Department of Veterans Affairs Veterans Integrated Service Network 2 (VA-VISN 2) awarded a Blanket Purchase Agreement (BPA) to Abbott Molecular Inc., a subsidiary of Abbott Laboratories, to provide nucleic acid and SARS testing services. The BPA, valued at up to $1.3 million, is based on Abbott Molecular's Federal Supply Schedule 66-III contract for Critical Analyzers, Laboratory products and services. Under this single-award IDV, Abbott Molecular will deliver real-time PCR testing capabilities, including equipment, reagents, and consumables, to support the VA's HIV, hepatitis C, and COVID-19 testing requirements at its facility in Des Plaines, Illinois. The contract has a base year and four option years, with task orders issued that range from 1 to 3 years in duration. No small business set-asides were utilized. As a leading provider of molecular diagnostics to federal agencies, Abbott Molecular's specialized testing platforms and proprietary reagents make it uniquely positioned to fulfill the VA's needs for comprehensive infectious disease testing solutions.

The original solicitation was a special notice issued by VA-VISN 2, citing the authority of the Multiple-Award Schedule Program, to procure nucleic acid detection testing capabilities on a limited sources basis from Abbott Molecular. The notice highlighted the specialized nature of the Abbott Molecular M2000 analyzer and reagents, which are the only offerings compatible with the VA's required testing for HIV, hepatitis C, and SARS-CoV-2. The solicitation provided estimated quantities and unit prices for the various test kits, with the intent to establish a multi-year BPA to ensure the VA's continued access to these critical diagnostic services.